XERS Quote, Financials, Valuation and Earnings

Editas Medicine has a net margin of -15.34% compared to Xeris Biopharma Holdings's net margin of -1633.49%. Xeris Biopharma Holdings's return on equity of -1019.2% beat Editas Medicine's return on equity of -139.77%.

Xeris Biopharma Holdings has a consensus price target of $6.42, signalling upside risk potential of 30.95%. On the other hand Editas Medicine has an analysts' consensus of $3.38 which suggests that it could grow by 144.57%. Given that Editas Medicine has higher upside potential than Xeris Biopharma Holdings, analysts believe Editas Medicine is more attractive than Xeris Biopharma Holdings.

Xeris Biopharma Holdings has a beta of 0.926, which suggesting that the stock is 7.36% less volatile than S&P 500. In comparison Editas Medicine has a beta of 2.149, suggesting its more volatile than the S&P 500 by 114.892%.

Xeris Biopharma Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Editas Medicine offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xeris Biopharma Holdings pays -- of its earnings as a dividend. Editas Medicine pays out -- of its earnings as a dividend.

Xeris Biopharma Holdings quarterly revenues are $60.1M, which are larger than Editas Medicine quarterly revenues of $4.7M. Xeris Biopharma Holdings's net income of -$9.2M is higher than Editas Medicine's net income of -$76.1M. Notably, Xeris Biopharma Holdings's price-to-earnings ratio is -- while Editas Medicine's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xeris Biopharma Holdings is 3.30x versus 3.18x for Editas Medicine. Usually stocks with elevated PS ratios are considered overvalued.

Ocugen has a net margin of -15.34% compared to Xeris Biopharma Holdings's net margin of -1036.46%. Xeris Biopharma Holdings's return on equity of -1019.2% beat Ocugen's return on equity of -215.5%.

Xeris Biopharma Holdings has a consensus price target of $6.42, signalling upside risk potential of 30.95%. On the other hand Ocugen has an analysts' consensus of $6.50 which suggests that it could grow by 835.79%. Given that Ocugen has higher upside potential than Xeris Biopharma Holdings, analysts believe Ocugen is more attractive than Xeris Biopharma Holdings.

Xeris Biopharma Holdings has a beta of 0.926, which suggesting that the stock is 7.36% less volatile than S&P 500. In comparison Ocugen has a beta of 4.214, suggesting its more volatile than the S&P 500 by 321.428%.

Xeris Biopharma Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ocugen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xeris Biopharma Holdings pays -- of its earnings as a dividend. Ocugen pays out -- of its earnings as a dividend.

Xeris Biopharma Holdings quarterly revenues are $60.1M, which are larger than Ocugen quarterly revenues of $1.5M. Xeris Biopharma Holdings's net income of -$9.2M is higher than Ocugen's net income of -$15.4M. Notably, Xeris Biopharma Holdings's price-to-earnings ratio is -- while Ocugen's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xeris Biopharma Holdings is 3.30x versus 42.96x for Ocugen. Usually stocks with elevated PS ratios are considered overvalued.

Ocular Therapeutix has a net margin of -15.34% compared to Xeris Biopharma Holdings's net margin of -598.74%. Xeris Biopharma Holdings's return on equity of -1019.2% beat Ocular Therapeutix's return on equity of -56.05%.

Xeris Biopharma Holdings has a consensus price target of $6.42, signalling upside risk potential of 30.95%. On the other hand Ocular Therapeutix has an analysts' consensus of $17.50 which suggests that it could grow by 152.53%. Given that Ocular Therapeutix has higher upside potential than Xeris Biopharma Holdings, analysts believe Ocular Therapeutix is more attractive than Xeris Biopharma Holdings.

Xeris Biopharma Holdings has a beta of 0.926, which suggesting that the stock is 7.36% less volatile than S&P 500. In comparison Ocular Therapeutix has a beta of 1.508, suggesting its more volatile than the S&P 500 by 50.759%.

Xeris Biopharma Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ocular Therapeutix offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xeris Biopharma Holdings pays -- of its earnings as a dividend. Ocular Therapeutix pays out -- of its earnings as a dividend.

Xeris Biopharma Holdings quarterly revenues are $60.1M, which are larger than Ocular Therapeutix quarterly revenues of $10.7M. Xeris Biopharma Holdings's net income of -$9.2M is higher than Ocular Therapeutix's net income of -$64.1M. Notably, Xeris Biopharma Holdings's price-to-earnings ratio is -- while Ocular Therapeutix's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xeris Biopharma Holdings is 3.30x versus 19.47x for Ocular Therapeutix. Usually stocks with elevated PS ratios are considered overvalued.

TG Therapeutics has a net margin of -15.34% compared to Xeris Biopharma Holdings's net margin of 4.19%. Xeris Biopharma Holdings's return on equity of -1019.2% beat TG Therapeutics's return on equity of 19.78%.

Xeris Biopharma Holdings has a consensus price target of $6.42, signalling upside risk potential of 30.95%. On the other hand TG Therapeutics has an analysts' consensus of $43.50 which suggests that it could grow by 30.24%. Given that Xeris Biopharma Holdings has higher upside potential than TG Therapeutics, analysts believe Xeris Biopharma Holdings is more attractive than TG Therapeutics.

Xeris Biopharma Holdings has a beta of 0.926, which suggesting that the stock is 7.36% less volatile than S&P 500. In comparison TG Therapeutics has a beta of 2.208, suggesting its more volatile than the S&P 500 by 120.838%.

Xeris Biopharma Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TG Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xeris Biopharma Holdings pays -- of its earnings as a dividend. TG Therapeutics pays out -- of its earnings as a dividend.

Xeris Biopharma Holdings quarterly revenues are $60.1M, which are smaller than TG Therapeutics quarterly revenues of $120.9M. Xeris Biopharma Holdings's net income of -$9.2M is lower than TG Therapeutics's net income of $5.1M. Notably, Xeris Biopharma Holdings's price-to-earnings ratio is -- while TG Therapeutics's PE ratio is 139.17x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xeris Biopharma Holdings is 3.30x versus 13.90x for TG Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.